

Neeta Somaiah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2464756/publications.pdf>

Version: 2024-02-01

77
papers

2,120
citations

236925

25
h-index

276875

41
g-index

77
all docs

77
docs citations

77
times ranked

3197
citing authors

#	ARTICLE	IF	CITATIONS
1	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	12.8	143
2	Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. <i>Cancer Research</i> , 2014, 74, 1645-1650.	0.9	139
3	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
4	Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. <i>Annals of Surgical Oncology</i> , 2014, 21, 2136-2143.	1.5	96
5	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	2.6	69
6	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , 2019, 25, 5808-5817.	7.0	66
7	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. <i>Modern Pathology</i> , 2015, 28, 587-595.	5.5	64
8	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	1.8	62
9	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
10	Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. <i>Cancer</i> , 2017, 123, 4640-4647.	4.1	61
11	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
12	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. <i>Journal of Immunotherapy</i> , 2017, 40, 302-306.	2.4	51
13	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	51
14	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. <i>Sarcoma</i> , 2015, 2015, 1-9.	1.3	48
15	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1335.e13-1335.e15.	1.7	46
16	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	4.6	46
17	Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002386.	1.2	45
18	Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results. <i>Cancers</i> , 2013, 5, 529-549.	3.7	43

#	ARTICLE	IF	CITATIONS
19	Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes. <i>Annals of Surgical Oncology</i> , 2015, 22, 1068-1072.	1.5	43
20	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3802-3810.	7.0	42
21	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1751-1764.	4.1	39
22	Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. <i>Annals of Surgical Oncology</i> , 2018, 25, 2193-2200.	1.5	34
23	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. <i>European Journal of Cancer</i> , 2017, 76, 76-83.	2.8	32
24	Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1188-1194.	1.7	31
25	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11514-11514.	1.6	30
26	Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. <i>Cancer Letters</i> , 2017, 403, 216-223.	7.2	29
27	Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018, 9, e1420450.	4.6	28
28	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. <i>Oncotarget</i> , 2018, 9, 19891-19899.	1.8	28
29	Potential for immunotherapy in soft tissue sarcoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3117-3124.	3.3	26
30	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	1.8	26
31	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24
32	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>Oncotarget</i> , 2020, 11, 1847846.	4.6	22
33	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	3.3	21
34	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	3.7	20
35	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019, 11, 677.	3.7	20
36	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19

#	ARTICLE	IF	CITATIONS
37	A Tabulated Summary of Targeted and Biologic Therapies for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, S342-S368.	1.1	18
38	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. <i>Laboratory Investigation</i> , 2016, 96, 885-894.	3.7	17
39	A Tabulated Summary of Targeted and Biologic Therapies for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 21-51.	2.6	16
40	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	16
41	New drugs and combinations for the treatment of soft-tissue sarcoma: a review. <i>Cancer Management and Research</i> , 2012, 4, 397.	1.9	15
42	Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 872-879.	0.9	15
43	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. <i>Scientific Reports</i> , 2017, 7, 9519.	3.3	15
44	Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 107-116.	1.5	15
45	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	4.1	15
46	Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11512-11512.	1.6	15
47	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
48	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11509-11509.	1.6	13
49	Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. <i>Cancer Medicine</i> , 2020, 9, 4593-4602.	2.8	12
50	A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. <i>Cancer</i> , 2021, 127, 894-904.	4.1	12
51	Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 871-882.	2.5	12
52	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. <i>Translational Oncology</i> , 2017, 10, 546-554.	3.7	11
53	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
54	Molecular profiling of sarcomas: new vistas for precision medicine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 243-255.	2.8	9

#	ARTICLE	IF	CITATIONS
55	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	4.1	9
56	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. <i>International Journal of Cancer</i> , 2022, 150, 2012-2024.	5.1	8
57	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 4092-4104.	7.0	8
58	Identification of preoperative factors associated with outcomes following surgical management of intraâ€abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. <i>Journal of Surgical Oncology</i> , 2018, 117, 879-885.	1.7	7
59	A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10564-10564.	1.6	7
60	Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210810.	3.2	7
61	Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	6
62	An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. <i>Current Oncology Reports</i> , 2016, 18, 49.	4.0	5
63	The degree of sclerosis is associated with prognosis in wellâ€differentiated liposarcoma of the retroperitoneum. <i>Journal of Surgical Oncology</i> , 2019, 120, 382-388.	1.7	5
64	Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. <i>Annals of Surgical Oncology</i> , 2021, 28, 570-575.	1.5	4
65	Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11039-11039.	1.6	4
66	Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. <i>Sarcoma</i> , 2017, 2017, 1-6.	1.3	3
67	Olaratumab in the management of advanced soft tissue sarcoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 442-448.	0.9	3
68	National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 9159-9168.	1.5	3
69	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11511-11511.	1.6	3
70	Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. <i>Future Oncology</i> , 2021, 17, 5007-5012.	2.4	3
71	ASO Visual Abstract: National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 457.	1.5	1
72	Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10558-10558.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 7553-7553.	1.6	1
74	Clinical Characteristics and Treatment Outcomes of Clear Cell Chondrosarcomas: MD Anderson Cancer Center Series.. Journal of Clinical Oncology, 2015, 33, 10531-10531.	1.6	0
75	Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations.. Journal of Clinical Oncology, 2015, 33, 10550-10550.	1.6	0
76	Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study.. Journal of Clinical Oncology, 2015, 33, e20714-e20714.	1.6	0
77	Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2019, 37, 11008-11008.	1.6	0